Method for enhancing expression of insulin like growth factor 1 receptor in mesenchymal stem cell, method for obtaining mesenchymal stem cell, and method for treating brain tissue damage

Patent metadata

Field	Value
Publication number	US-11529373-B2
Application number	US-202016835771-A
Country	US
Kind code	B2
Filing date	Mar 31, 2020
Priority date	Jul 22, 2015
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

A method for enhancing an expression of insulin like growth factor 1 receptor in a mesenchymal stem cell is provided. The method includes culturing the mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the mesenchymal stem cell.

First claim

What is claimed is:

1. A method for treating a brain tissue damage, the method comprising administering a composition containing a plurality of umbilical cord mesenchymal stem cells to a subject in need for a treatment of the brain tissue damage, wherein the umbilical cord mesenchymal stem cell is isolated from Wharton's jelly, and is insulin-like growth factor 1 receptor positive selected by using an insulin-like growth factor 1 receptor antibody and then cultured in a medium containing platelet-derived growth factor BB (PDGF-BB) at 2.5-50 ng/mL to enhance the expression of insulin-like growth factor 1 receptor in the mesenchymal stem cell;
wherein the brain tissue damage results from a cerebral ischemic disease.

2. The method of claim 1 , wherein the cerebral ischemic disease is a stroke.

3. The method of claim 1 , wherein the medium further comprises a cytokine selected from a group consisting of epidermal growth factor (EGF), angiogenin (ANG), macrophage inflammatory protein-5 (MIP-1δ), regulated on activation, normal T-cell expressed and presumably secreted (RANTES), and a combination thereof.

4. The method of claim 1 , wherein a source of the PDGF-BB is human cord blood serum.

Assignees

• Univ China Medical

Inventors

• Shyu Woei-Cherng
• Lin Chen-Huan
• Lee Wei
• Hsieh Chia-Hung
• Hsu Chung-Y
• TSAI Chang-Hai

Classifications

• C12N5/0665

  Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K35/28 Primary

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C12N2500/84

  from mammals · CPC title

• A61K38/1858

  Platelet-derived growth factor [PDGF] · CPC title